DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Type 2 Diabetes Mellitus - Heat Map and Analysis" report to their offering.
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large, diverse and rapidly growing market landscape, comprising numerous different drug classes.
In particular, the emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter-2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful, leading to considerable market growth. With a highly active late-stage pipeline, this trend is expected to continue over the coming years.
Differences between these products must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all major late-stage clinical trial results for products in the T2DM market and late-stage pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and control groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
- What are the clinical characteristics of currently approved therapies for T2DM, in terms of specific safety and efficacy parameters?
- Will metformin continue to be the preferred first-line therapy?
- How will established drug classes such as the GLP-1 receptor agonists be impacted by upcoming pipeline competitors?
- Will biosimilar erosion significantly impact the insulin market?
- What technologies are late-stage pipeline therapies employing to improve patient convenience and ease of use?
Key Topics Covered:
1. Table of Contents
2.1 Report Guidance
3. Marketed Products
3.2 Non-insulin Monotherapy
3.3 Non-insulin Combination Therapy
3.4 Insulin and Non-insulin Combination Therapy
4. Pipeline Products
4.2 Changes to Non-Insulin Monotherapy, 2016-2022
4.3 Changes to Non-insulin Combination Therapy, 2016-2022
4.4 Changes to Insulin and Non-insulin Combination Therapy, 2016-2022
For more information about this report visit http://www.researchandmarkets.com/research/2lkhjv/type_2_diabetes